突然宣布！院士董事长辞职

Core Viewpoint - The sudden resignation of Xiao Wei as the chairman of Kangyuan Pharmaceutical raises questions about the company's future direction amid declining performance [1][3]. Group 1: Leadership Changes - Xiao Wei has resigned as the chairman of Kangyuan Pharmaceutical but will continue to serve as a director and hold other committee positions [3]. - He has been the chairman since November 2000 and is recognized as the founder and actual controller of the company [3][4]. - The company will soon complete the election of a new chairman, and Xiao Wei's resignation does not affect the board's operational capacity [3]. Group 2: Financial Performance - In 2024, Kangyuan Pharmaceutical reported a revenue of 3.898 billion yuan, a year-on-year decrease of 19.86%, and a net profit of 392 million yuan, down 15.58% [6][7]. - The downward trend continued into the first quarter of 2025, with revenue declining by 35.38% and net profit decreasing by 38.37% year-on-year [7]. - The company has faced challenges in meeting performance targets, leading to the cancellation of stock incentive plans for 155 employees [7][8]. Group 3: Market Context - The company focuses on traditional Chinese medicine, particularly in areas such as respiratory and cardiovascular diseases, and is also expanding into biopharmaceuticals [6]. - There has been a trend of state-owned enterprises acquiring private Chinese medicine companies, indicating a shift in the industry landscape [8][10]. - As of June 20, Kangyuan Pharmaceutical's stock closed at 14.73 yuan per share, with a market capitalization of 8.34 billion yuan [11].